# Safety and Efficacy of APRIL-BAFF-Bicephali CAR-T in Relapsed, Refractory Multiple Myeloma

> **NCT06132711** · PHASE1,PHASE2 · RECRUITING · sponsor: **Xuzhou Medical University** · enrollment: 20 (estimated)

## Conditions studied

- Multiple Myeloma

## Interventions

- **OTHER:** APRIL-BAFF-Bicephali CAR-T cells

## Key facts

- **NCT ID:** NCT06132711
- **Lead sponsor:** Xuzhou Medical University
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-11-10
- **Primary completion:** 2026-01-01
- **Final completion:** 2027-01-01
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2023-11-15

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06132711

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06132711, "Safety and Efficacy of APRIL-BAFF-Bicephali CAR-T in Relapsed, Refractory Multiple Myeloma". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT06132711. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*